Following Eli Lilly?
Get the free weekly M&A digest
The latest M&A deals, like Eli Lilly’s — who’s behind them and what they mean, delivered to your inbox every week. No credit card, unsubscribe anytime.
Weekly Digest
New M&A deals, summarized for you
Straight to Inbox
No login, no app to check — it comes to you
Deal Trends
See who's moving and how much in your market
No credit card required Weekly M&A digest
Acquiring Company
Eli Lilly
Acquired Company
Ajax Therapeutics
IndianapolisManufacturingBiotechnologyHealth CarePharmaceuticalBiotechnologyHealth CareTherapeuticsPharmaceuticalBiopharmaDescription
Eli Lilly is acquiring Ajax Therapeutics for up to $2.3 billion, marking its third oncology deal in three weeks. This acquisition focuses on Ajax's lead program AJ1-11095, a promising treatment for rare blood cancers. The deal will enhance Lilly's portfolio in hematology and oncology, expanding its presence in blood-based cancers. The acquisition includes milestone payments alongside an undisclosed upfront payment.
Related People
M&A Insights
Based on deal dataIntegration timeline
70% of M&A integrations take 12-24 months to complete
Tech stack consolidation
83% of merged companies consolidate technology vendors within first year
Post-acquisition investment
Companies increase IT spending by 23% on average after acquisitions
Success factor
M&A deals with strong technology integration plans are 2.5x more likely to succeed